- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Issues Alert About Fluid-Filled Balloons to Treat Obesity
So far, the adverse events have been reported for the 2 fluid-filled designs, not for an air-filed design later approved.
The FDA has alerted healthcare providers about reports of adverse events from the fluid-filled balloons approved over the past 2 years to treat obesity.
The FDA’s February 9, 2016, notice reports 2 types of events:
- The balloons overinflate with air or more fluid, requiring early removal.
- Patients develop acute pancreatitis, although how this occurs is unknown.
In 2015, the FDA approved 2 fluid-filled balloon systems, the ReShape integrated dual balloon system, and the Orbera balloon system. ReShape uses 2 balloons, while Orbera uses 1 balloon. Both systems place the balloons into the stomach through the mouth, using an endoscopic procedure.
In 2016, the FDA has also approved the Obalon system, which uses a swallowable capsule to place up to 3 balloons. The capsule is attached to a catheter used to fill the balloons with air. So far, the FDA, reports, the adverse events reported have not affected this balloon system.
The FDA reminds providers to report any adverse reactions through its MedWatch system, which can be found here.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
